Identification of a novel long non-coding RNA within RUNX1 intron 5

Human Genomics
Nicolás SchnakeSoraya E Gutiérrez

Abstract

RUNX1 gene, a master regulator of the hematopoietic process, participates in pathological conditions as a partner for several genes in chromosomal translocations. One of the most frequent chromosomal translocations found in acute myeloid leukemia patients is the t(8;21), in which RUNX1 and ETO genes recombine. In RUNX1 gene, the DNA double-strand breaks that originate the t(8;21) are generated in the intron 5, specifically within three regions designated as BCR1, BCR2, and BCR3. To date, what determines that these regions are more susceptible to DNA double-strand breaks is not completely clear. In this report, we characterized RUNX1 intron 5, by analyzing DNase-seq and ChIP-seq data, available in the ENCODE Project server, to evaluate DNaseI hypersensitivity and the presence of the epigenetic mark H3K4me3 in 124 and 51 cell types, respectively. Our results show that intron 5 exhibits an epigenetic mark distribution similar to known promoter regions. Moreover, using the online tool YAPP and available CAGE data from the ENCODE Project server, we identified several putative transcription start sites within intron 5 in regions BCR2 and BCR3. Finally, available EST data was analyzed, identifying a novel uncharacterized long non-codi...Continue Reading

References

Jun 1, 1995·Genes & Development·T Kiss, W Filipowicz
Aug 1, 1994·Leukemia & Lymphoma·G Nucifora, J D Rowley
Aug 30, 2001·Proceedings of the National Academy of Sciences of the United States of America·Y YuanD E Zhang
Feb 28, 2002·Proceedings of the National Academy of Sciences of the United States of America·Yanming ZhangJanet D Rowley
Oct 15, 2008·Journal of Cellular Physiology·Marcela StuardoSoraya E Gutiérrez
Nov 13, 2010·Nucleic Acids Research·David RearickAlexei Fedorov
Dec 23, 2010·Future Oncology·Etienne De BraekeleerMarc De Braekeleer
Apr 23, 2014·International Journal of Cancer. Journal International Du Cancer·Hong WangJi-Fan Hu
Dec 3, 2014·Experimental Cell Research·C Drevon, T Jaffredo
Jul 20, 2017·Journal of Translational Internal Medicine·Ming Hong, Guangsheng He
Aug 16, 2017·Seminars in Cell & Developmental Biology·Vincent BoivinMichelle S Scott
Apr 29, 2018·Molecular Cancer·Joëlle El HajjEvelyne Ségal-Bendirdjian

❮ Previous
Next ❯

Citations

Aug 28, 2021·Genes·Amarni L ThomasJulia A Horsfield

❮ Previous
Next ❯

Datasets Mentioned

BETA
AA984901

Methods Mentioned

BETA
chromosomal aberrations
acetylation
ChIP-seq
PCR
Assay
electrophoresis

Software Mentioned

Nucleotide BLAST (
nBLAST )
YAPP Eukaryotic Core Promoter Predictor
ENCODE
Nucleotide BLAST
YAPP
Eukaryotic Core Promoter Predictor

Related Concepts

Related Feeds

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

Allergy and Asthma

Allergy and asthma are inflammatory disorders that are triggered by the activation of an allergen-specific regulatory t cell. These t cells become activated when allergens are recognized by allergen-presenting cells. Here is the latest research on allergy and asthma.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.